To the content
Leven met Sjögren

Iinalumab shows a positive effect on Sjögren's

News

Ianalumab significantly reduces disease activity in patients with Sjögren's syndrome. This is evident from 2 phase III studies (NEPTUNUS-1 and -2). It is the first drug to show a convincing effect on systemic autoimmune disease.

Sjögren's is characterized by B-cell hyperactivity and a disrupted BAFF/BAFF-R signaling pathway. Iinalumab is a human monoclonal IgG1 antibody that inhibits the interaction between the B-cell activating factor BAFF and the receptor of this inflammatory protein, BAFF-R, through a dual mechanism of action and also reduces the number of B cells.

Superiority

In the 2 double-blind, placebo-controlled studies, a total of 504 adults with moderate disease activity (≥ 5 points on EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)) randomized to monthly ianalumab 300 mg subcutaneously or placebo. In NEPTUNE-2, a three-monthly dose was also investigated. Patients were allowed to continue taking their existing immunosuppressants (methotrexate, hydrochloroquine, azathioprine and low doses of prednisone). The primary endpoint of both studies was superiority compared to placebo after 48 weeks.

Statistically significant

In NEPTUNE-1, the group with monthly ianalumab scored significantly better on the ESSDAI than the placebo group after 48 weeks. Ianalumab also scored significantly better on the secondary outcome measures patient- and physician-reported general assessment (PaGA and PhGA), indicating fewer symptoms and lower perceived disease activity. Furthermore, ianalumab had a favorable safety profile. The incidence of (serious) side effects was comparable to that in the placebo group.

Important step

Principal investigator Thomas Grader-Beck from Johns Hopkins (Maryland) said at the presentation that these results confirm that BAFF-R inhibition combined with B-cell depletion can be an effective strategy for reducing disease activity in Sjögren's. The results represent an important step towards the first approved systemic therapy for this complex autoimmune disease.

Source: mednet.nl

Back to the overview

More news